(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic - 2NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- 3Turning into a Sharp Financial backer: Individual budget Wins
- 4Mojtaba Khamenei unconscious in Qom, not actually running Iran
- 5Pick Your Favored method of transportation
- 'Senseless violence' erupts at Christmas tree lighting; 4 injured
- Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- 10 Natural products to Remember for Your Eating routine for a Better You
- Major railway disruptions persist as Germany braces for more snow
- Pick Your #1 Kind Of Bread
- ‘It’s Israeli policy’: Report reveals abuse of Palestinians in prisons
- Indian Health Service is digging out of decades-old construction backlog for medical buildings
- The Best Internet based Courses for Expertise Improvement
